| Thank you for reading our monthly newsletter. This month’s edition is 1,175 words, about a 4-minute read. | | Want to get the Elysium Newsletter in your inbox? Sign up here. | | | | | Ten years ago, we set out with a clear mission: advance the science of aging and provide people with meaningful tools to shape their long-term health. With science as the foundation, that mission has guided every discovery, every partnership, and every product we have developed.
Over the past decade, members of our Scientific Advisory Board—including eight Nobel Prize winners—have worked closely and continuously with us to help guide our research and product development. Every one of our longevity products has been developed with input from leading scientists and physicians, including our chief scientist Leonard Guarente, Ph.D. (MIT), Theodore Leng, M.D. (Stanford), A. David Smith (Oxford), Richard Granstein, M.D. (Cornell), and Morgan Levine, Ph.D. (Yale).
To our customers: Thank you for trusting us, and for being part of this important work. We’re grateful for the role you’ve played in helping shape Elysium’s first 10 years, and we’re excited for the next 10—and the next 10. |  | Eric Marcotulli
Elysium CEO and co-founder | | | | | | |  | | NAD+ goes mainstream—with Basis and Signal leading the way | |  | | | | With Elysium-led and Elysium-supported clinical research, we’ve helped elucidate the role of NAD+ in healthy aging. This is the science Elysium is built on. The journey began in the early 2000s, when Dr. Leonard Guarente’s lab in Cambridge, MA, discovered the critical link between NAD+, sirtuins, and aging. Since then, NAD+ has moved to the center of the longevity conversation. Recently, we hit a major milestone with one of the most important NAD+ findings to date: Among more than 4,000 people, long-term users of Basis and Signal aged more slowly than non-users—showing an average biological age advantage of 2.5 years after 2.5 years.* A striking one-to-one effect, and a clear signal that NAD+ is a pillar of modern longevity science. The manuscript is under preparation for publication. | | | | | | | | | | | |  | | 17+ clinical trials and counting | | | Elysium’s clinical research aims to promote high-quality evidence in longevity science. It started with our Repeat Dose Basis study—one of the top 10 most cited NAD+ clinical trials and among the top 1.8% of the most cited papers worldwide. Across 17+ clinical trials, our research has advanced the understanding of NAD+ metabolism and its role in inflammatory responses, neuroprotection, and biological aging. As Elysium co-founder and chief scientist Leonard Guarente, Ph.D., puts it: “What is striking is how Elysium products continue to be validated by experimental data, including human trials, and position the company as the leader in promoting healthy aging.” | | | | | | | | | | | | | |  | | Elysium’s Scientific Advisory Board achieves global recognition | | | Elysium’s Scientific Advisory Board has been instrumental in guiding the scientific direction of our company. Many of the members have been with us for the entire decade—including Nobel laureates Eric Kandel, Ph.D., and Jack Szostak, Ph.D., and pioneering microbiome researcher Martin Blaser, M.D., among others. Carolyn Bertozzi, Ph.D., received the 2022 Nobel Prize in Chemistry, while several advisors were named Highly Cited Researchers, placing them among the top 1% in their fields. Our advisors also play central roles in ongoing research and product development. We’re grateful for the ongoing contributions of these world-class scientists and clinicians. | | | | | | | | | | | |  | |  ,  , and more: Elysium leads the longevity conversation | |  | | | | Longevity science has moved into the mainstream, and Elysium is defining that shift. Alongside our chief scientist Leonard Guarente, Ph.D., Elysium has been featured in top-tier publications including The Wall Street Journal, TIME, Bloomberg, TODAY, WIRED, CNN, STAT, and The New Yorker, as well as leading lifestyle magazines like Vogue, GQ, and Harper’s Bazaar. As The Wall Street Journal put it in its profile of him, Dr. Guarente is the “grandfather of the longevity movement.” | | | | | | | | | | | |  | | EH301 earns Orphan Drug Designation | | | The development of EH301 marked one of Elysium’s most significant clinical milestones. The experimental therapeutic received FDA Orphan Drug Designation for the treatment of amyotrophic lateral sclerosis (ALS), a rare and devastating neurodegenerative disease affecting fewer than 200,000 people in the U.S. This designation followed results from a double-blind, placebo-controlled pilot study in Europe, where EH301 showed evidence of slowing ALS progression and improving key clinical measures. | | | | | | | | | | | |  | | Index sets a new
benchmark for measuring biological aging | |  | | | | Launched in 2019, Index redefined how biological age is measured. Developed with leading epigenetics researcher Morgan Levine, Ph.D., it analyzes global methylation patterns with greater reliability than other epigenetic clocks—with results published in Nature Aging. In 2023, Index expanded to track system-level aging across nine areas of health. Along with system age measures, Elysium launched the Aging Research Center (ARC)—a first-of-its-kind digitally-native research effort that aims to better our collective understanding of aging by building the world's most actionable epigenetic dataset. Through ARC’s longitudinal studies, including TIME-A and TIME-ZZZ, Elysium is setting a new standard for understanding how we age, while offering people an opportunity to participate directly in longevity research. | | | | | | | | | | | |  | | Elysium’s product portfolio targets the hallmarks of
aging | |  | | | | As our understanding of aging deepened, so did our products. What began with Basis expanded as science revealed how interconnected the systems of aging truly are. Today, Elysium’s portfolio targets multiple hallmarks of aging, and each product is developed with the guidance of leading scientists—reflecting a more complete, systems-level view of longevity. As Dr. Leonard Guarente puts it, “We are optimistic that the course of human health could be fundamentally changed.” | | | | | | | | | | | |  | | Webinars brought world-class science to our community | |  | | | | | | | | | | | | | |  | | Partnerships that drove breakthroughs | | | Collaboration defined Elysium’s first decade. Our official partners and investors—including Yale, Oxford, Harvard, and Mayo Clinic—helped advance studies across core drivers of aging and develop category-leading products. Together, this global network of scientists and institutions shaped many of our most impactful discoveries and continues to drive the research underway today. | | | | | | | | | | | |  | | A new era for Elysium’s packaging and design | |  | | | | To close our first decade, we introduced new packaging that reflects our long-term commitment to quality and sustainability—packaging that’s truly Built for Longevity. The copper-plated stainless steel jars are perfect for the counter (not the cupboard), while monthly refill pouches reduce plastic waste each month by 89%. The updated system provides packaging as durable and enduring as our mission. | | | | | | | |  | | QUOTE OF THE MONTH | | “When Elysium added Signal to balance the benefits of Basis, I jumped on board. I have been taking them together ever since. I suggest that new customers (and those only taking Basis) subscribe to both in order to get the maximum benefit of each. It's a MUST.” | | – Donna A. | | | | | Share your healthy aging breakthroughs | | | | | We’d love to hear from you! If you have a story to share about your experience with Elysium products, we want to celebrate your health journey. Please email [email protected] and your story may be featured in an upcoming newsletter or on our social media channels. | | | | |
